Key facts
- This page summarizes George A. Eldridge's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 18:00.
George A. Eldridge - 14 Jun 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Officer Title: Chief Financial Officer and Treasurer
- Issuer ticker
- JBIO
- Reported as of
- 14 Jun 2024
- Net transaction value
- -$343,350
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 18:00:09 UTC
- Prior SEC filing
- 12 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
George A. Eldridge filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 12 Apr 2024.
- Current net transaction value: -$343,350.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $32,100
- Shares
- +15,000
- Change %
- +299%
- Price
- $2.14*
- Shares after
- 20,022
- Date
- 14 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AVTE
transaction
Common Stock
Sale
- Transaction value
- $375,450
- Shares
- -15,000
- Change %
- -75%
- Price
- $25.03
- Shares after
- 5,022
- Date
- 14 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -34%
- Price
- $0.000000
- Shares after
- 28,763
- Date
- 14 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $2.14
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
Footnote F2
Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).
Footnote F3
A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
SEC remarks
Officer Title: Chief Financial Officer and Treasurer